OTC Markets Group Welcomes Antibe Therapeutics Inc. to OTCQX

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has qualified to trade on the OTCQX® Best Market. Antibe Therapeutics Inc. upgraded to OTCQX from the OTCQB® Venture Market.

Antibe Therapeutics Inc. begins trading today on OTCQX under the symbol "ATBPF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

"We are delighted to upgrade to the OTCQX Best Market," remarked Scott Curtis, Executive VP of Antibe. "This initiative advances our capital markets strategy by emphasizing our commitment to transparency, enhancing liquidity and expanding access to our stock for U.S. and international investors."

About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with NSAIDs. Antibe's lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin.

(PRNewsfoto/OTC Markets Group Inc.)

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-antibe-therapeutics-inc-to-otcqx-301227994.html

SOURCE OTC Markets Group Inc.


Company Codes: OTC-PINK:OTCM, OTC-PINK:ATBPF, Toronto:ATE, OTC-QX:ATBPF, OtherOTC:ATBPF, OtherOTC:OTCM

Back to news